Nihar R. Desai, MD, MPH

Discover the critical importance of early LDL lowering with PCSK9 inhibitors to reduce cardiovascular risks and improve patient outcomes.

Explore the mechanisms and differences between PCSK9 inhibitors, including monoclonal antibodies and siRNA, in lowering LDL cholesterol effectively.

Experts discuss barriers to effective lipid-lowering therapy, emphasizing the need for systematic approaches and early combination treatments to improve patient outcomes.

This program brings together leading experts to discuss evolving strategies for reducing recurrent cardiovascular risk in patients with ASCVD, emphasizing the importance of cumulative LDL-C exposure and the need for earlier, more intensive lipid lowering. The panel explores current guidelines, emerging data from recent trials, and practical approaches to integrating PCSK9-targeting therapies to improve long-term adherence, access, and outcomes in secondary prevention

This program brings together leading experts to discuss evolving strategies for reducing recurrent cardiovascular risk in patients with ASCVD, emphasizing the importance of cumulative LDL-C exposure and the need for earlier, more intensive lipid lowering. The panel explores current guidelines, emerging data from recent trials, and practical approaches to integrating PCSK9-targeting therapies to improve long-term adherence, access, and outcomes in secondary prevention

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

Panelists discuss how the future of low-density lipoprotein cholesterol (LDL-C) management in patients with post-acute coronary syndrome (ACS) will involve more aggressive LDL-C target levels, expanded use of PCSK9 inhibitors (PCSK9i), emerging lipid-lowering therapies, personalized medicine, and the integration of lifestyle modifications and digital health tools to improve patient outcomes.

Panelists discuss how research gaps in low-density lipoprotein cholesterol (LDL-C) management for high-risk populations, as highlighted by the VICTORION-INCEPTION study, include the need for long-term outcome data, combination therapy insights, and tailored approaches for diverse patient groups, alongside further investigation into safety, tolerability, and optimal LDL-C target levels.

Panelists discuss how barriers to implementing early PCSK9 inhibition, including financial constraints, strict clinical guidelines, patient concerns, and clinician unfamiliarity, can be overcome through strategies such as patient education, advocating for insurance support, and streamlining clinical workflows.

Panelists discuss how adherence to PCSK9 inhibitors (PCSK9i) can be influenced by factors such as injection frequency, cost, and patient education, with improved adherence seen when patients are supported in managing injections and provided with financial assistance.

Panelists discuss how early initiation of PCSK9 inhibitors (PCSK9i), particularly in patients with high-risk post-acute coronary syndrome (ACS) with elevated low-density lipoprotein cholesterol (LDL-C) levels or inflammatory biomarkers, can significantly reduce recurrent cardiovascular events and improve long-term outcomes.

Panelists discuss how inclisiran’s sustained LDL-lowering effect, safety profile, and ease of biannual administration position it as a transformative therapy for overcoming persistent gaps in post-ACS event care, as highlighted by real-world findings from the VICTORION-INCEPTION study.

Panelists discuss how inclisiran’s biannual dosing and early use after ACS events, as demonstrated in the VICTORION-INCEPTION study, offer a practical and effective strategy for sustained LDL reduction, improved adherence, and enhanced cardiovascular outcomes when combined with statin therapy.

Panelists discuss how the VICTORION-INCEPTION study highlights the benefits of early initiation of PCSK9 inhibitors (PCSK9i; specifically inclisiran) in patients with post-acute coronary syndrome (ACS), demonstrating significant low-density lipoprotein cholesterol (LDL-C) level reduction, lower rates of major cardiovascular events, and improved outcomes through aggressive lipid-lowering therapy.

Panelists discuss how the 2 available PCSK9 inhibitors (PCSK9i), alirocumab and evolocumab, provide effective low-density lipoprotein cholesterol (LDL-C) level lowering for high-risk patients, including those with acute coronary syndrome or familial hypercholesterolemia, especially when statin therapy alone is insufficient or not tolerated.

Panelists discuss how recent randomized clinical trials (RCTs) highlight the significant benefits of PCSK9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS), showing rapid low-density lipoprotein cholesterol (LDL-C) reduction, positive impacts on coronary atherosclerosis, and a reduction in major cardiovascular events.

Panelists discuss how achieving the low-density lipoprotein cholesterol (LDL-C) target level within 4 to 6 weeks after an acute coronary syndrome (ACS) event remains challenging for many patients due to factors such as suboptimal statin adherence, inadequate treatment intensity, patient concerns, and limited access to additional therapies.

Panelists discuss how while lowering low-density lipoprotein cholesterol (LDL-C) to very low levels can be safe and beneficial in high-risk patients, particularly after an acute coronary syndrome (ACS) event, an individualized approach and careful monitoring are essential to balance the benefits of LDL-C level reduction with potential risks.

Panelists discuss how managing low-density lipoprotein cholesterol (LDL-C) levels through high-intensity statin therapy and additional lipid-lowering agents following an acute coronary syndrome (ACS) event is critical for secondary prevention, with current guidelines recommending aggressive LDL-C level reduction to lower the risk of recurrent cardiovascular events.

Panelists discuss how patients with recent acute coronary syndrome (ACS) are at an elevated risk for recurrent cardiovascular events due to factors such as plaque instability, inflammation, endothelial dysfunction, and residual risk despite treatment, emphasizing the need for intensive secondary prevention strategies.

Panelists discuss how lowering low-density lipoprotein cholesterol (LDL-C) levels remains a central strategy for preventing atherosclerotic cardiovascular disease (ASCVD), emphasizing the importance of managing cholesterol years to reduce long-term cardiovascular risk.